Physician profile
Stephen Yau
NPI 1154616035
$983,671.95
in general payments reported to CMS, 2019-2025
13 companies · $3,635 in 2025
The $3,635 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $159 · 2021: $31K · 2022: $164K · 2023: $373K · 2024: $413K · 2025: $3,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $681K · Travel and Lodging: $78K · Food and Beverage: $17K · Consulting Fee: $13K · Education: $63.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $681,091.85 |
| Travel and Lodging | $77,849.23 |
| Food and Beverage | $16,759.84 |
| Consulting Fee | $13,459.50 |
| Education | $63.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $335,330.69 | 2022-2024 | Arexvy, Nucala, Trelegy Ellipta |
| Genzyme Corporation | $278,071.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $208,028.60 | 2022-2024 | Tezspire, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $126,012.30 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,515.64 | 2022-2025 | Ofev |
| Amgen INC. | $7,754.35 | 2022-2023 | Tezspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $355.55 | 2021-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $153.98 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $121.04 | 2019 | |
| Jazz Pharmaceuticals INC. | $111.60 | 2020 | |
| Bardy Diagnostics, INC. | $109.60 | 2021 | |
| Harmony Biosciences LLC | $91.35 | 2020-2021 | |
| Insmed, INC. | $16.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Yau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.